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Background: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX)
Syndrome is a rare recessive disorder caused by mutations in the FOXP3 gene. In
addition, there has been an increasing number of patients with wild-type FOXP3 gene
and, in some cases, mutations in other immune regulatory genes.
Objective: To molecularly asses a cohort of 173 patients with the IPEX phenotype
and to delineate the relationship between the clinical/immunologic phenotypes and the
genotypes.
Methods: We reviewed the clinical presentation and laboratory characteristics of each
patient and compared clinical and laboratory data of FOXP3 mutation-positive (IPEX
patients) with those from FOXP3 mutation-negative patients (IPEX-like). A total of 173
affected patients underwent direct sequence analysis of the FOXP3 gene while 85 IPEX-
like patients with normal FOXP3 were investigated by a multiplex panel of “Primary
Immune Deficiency (PID—related) genes.”
Results: Forty-four distinct FOXP3 variants were identified in 88 IPEX patients, 9
of which were not previously reported. Among the 85 IPEX-like patients, 19 different
disease-associated variants affecting 9 distinct genes were identified.
Conclusions: We provide a comprehensive analysis of the clinical features and
molecular bases of IPEX and IPEX-like patients. Although we were not able to identify
major distinctive clinical features to differentiate IPEX from IPEX-like syndromes, we
propose a simple flow-chart to effectively evaluate such patients and to focus on the
most likely molecular diagnosis. Given the large number of potential candidate genes and
overlapping phenotypes, selecting a panel of PID-related genes will facilitate a molecular
diagnosis.
Keywords: immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX), IPEX-like, FOXP3, regulatory
T cells, immune regulatory genes
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INTRODUCTION
The Immune dysregulation, Polyendocrinopathy, Enteropathy,
X-linked (IPEX) syndrome is a rare hemizygous disorder that
presents most commonly in early infancy, but may occur
antenatally (1) or later in life (2). The syndrome is characterized
by severe enteropathy, chronic dermatitis, early onset type
I diabetes mellitus (T1DM), hypoparathyroidism, antibody-
mediated cytopenias, and other autoimmune phenomena (2).
Affected males typically die within the first or second year of
life if not treated with immunosuppressive agents or cured by
hematopoietic stem cell transplantation (HSCT). IPEX was first
recognized clinically in 1982 by Powell et al. who described a
large kindred of five generations with 21 affected males who
had all died prematurely (2). Linkage analysis localized the
genetic defect to the centromeric region of the X chromosome
(Xp11.23–Xq13.3) near the gene for Wiskott-Aldrich Syndrome
(3, 4). Subsequently, mutations in the FOXP3 gene, which
codes for a DNA-binding factor with homology to Forkhead
family proteins, were found to be associated with the IPEX
syndrome (5–8), following the discovery of a frameshift mutation
in Foxp3 observed in a naturally occurring mutant mouse
(9). The scurfy mouse was described more than 55 years
ago (10) as an X-linked disease that shares many phenotypic
features with IPEX, including scaly skin, runting, diarrhea,
progressive anemia, lymphadenopathy and hepatosplenomegaly
(10, 11).
Subsequent studies have demonstrated that the clinical
phenotype of the scurfy mouse is the result of immune
dysregulation and loss of peripheral tolerance mechanisms due
to uncontrolled proliferation of activated CD4+ effector cells
(12, 13) and absence of CD4+CD25+ regulatory T cells (Treg)
(14). Extensive multi-organ infiltration with lymphocytes and
increased production of multiple cytokines result in death of
affected mice by 3–4 weeks of age (10–13, 15). Foxp3 is a
key modulator of Treg development as it orchestrates the
transcriptional machinery to induce Treg-relevant genes, such as
Il2ra (CD25) and Ctla4 (16) and by acting as a transcriptional
repressor (14, 17–19).
As in the mouse, FOXP3 is the key factor in human
Treg development and competitiveness, and its function has
been extensively investigated (20–23). In normal individuals
5–7% of CD4+ T cells have the characteristic properties of
Tregs. In addition to the Treg population that develops in the
thymus, referred to as natural Treg (nTreg) cells, there are
Tregs that are “induced” in the periphery from naïve CD4+
effector cells, identified as iTregs (24). Helios, a member of
the Ikaros family of transcription factors, is highly enriched
in nTregs in contrast to iTregs, a fact that has been used as
a marker of Tregs of thymic origin (25). FOXP3+ Treg cells
express a number of cell surface molecules that play unique
roles in the maintenance (CD25), trafficking (CD103), and
Abbreviations: IPEX, Immune dysregulation, Polyendocrinopathy, Enteropathy,
X-linked; PID, Primary Immune Deficiency; FOXP3, Forkhead box P3; T1DM,
Type 1 diabetes mellitus; HSCT, Hematopoietic Stem Cell Transplantation; Treg,
Regulatory T cells.
function (CTLA4) of regulatory T cells (26, 27). Down-regulation
of the IL-7 receptor α (CD127) is another useful marker to
identify Treg cells (CD4+CD25highFOXP3highCD127low) (28).
Tregs exert their suppressive effect either by direct cell-cell
contact, allowing immunoregulatory receptors such as CTLA4
to engage and down regulate antigen-presenting cells including
activated B cells via co-stimulatory molecules (CD80/CD86),
or by secreting immunoregulatory cytokines such as IL-10
and TGFβ that suppress bystander effector cells without direct
cell-cell contact (29, 30). Finally, CD25-expressing Treg cells
may induce suppression by acting as “IL-2 sink” through the
efficient absorption of free IL-2 by the overexpressed IL-2
receptor α (CD25), thus depriving effector cells of this crucial
cytokine (31).
In addition to “classic IPEX” caused by mutations in
FOXP3, there is an increasing group of patients with an IPEX-
like phenotype in the presence of a wild-type FOXP3 gene
that are being investigated for single gene defects other than
FOXP3. Examples are mutations in CD25 or STAT5b, genes
that code for molecules that are required for homeostasis,
fitness and maintenance of Treg cells (32, 33) or heterozygous
mutation in CTLA4 resulting in CTLA4 haploinsufficiency,
causing decreased capacity to mediate cell contact-dependent
suppression (34). More recently, mutations in LRBA have
been reported as a cause of IPEX-like clinical manifestations
characterized by early-onset enteropathy and endocrinopathies
(35). Moreover, mutations affecting genes that regulate the JAK-
STAT signaling pathways activated by T and B cell receptors
have recently been identified as causing immune dysregulation
with an IPEX-like phenotype. Included in this group of gene
defects are heterozygous activating mutations in the PI3 kinase
subunit p110δ encoded by PIK3CD and the PI3K subunit
p35 encoded by PIK3R1, and gain of function mutations
(GOF) in STAT1 and STAT3 (36–40). Abnormal activation
of innate immunity can also drive systemic autoimmune
diseases such as heterozygous germline mutations in tumor
necrosis factor-alpha-induced protein 3 (TNFAIP3), which
encodes a negative regulator of the nuclear factor-κB (NF-κB)
pathway (41).
In this collaborative study, involving Seattle Children’s
Research Institute (Seattle, USA) and Anna Meyer Children’s
Hospital, (Florence, Italy) we evaluated 173 affected males from
143 unrelated families with a clinical phenotype suggestive
of IPEX. Starting in 2001, we sequenced the FOXP3 gene
using genomic DNA from each qualifying patient. To more
clearly delineate the relationship between the clinical and
immunologic phenotypes and the genotype, we reviewed
the clinical and laboratory presentation of each patient to
determine if there are particular phenotypic features that
are typical for IPEX and are more predictive of a FOXP3
mutation.
Because half of the patients, whose phenotype suggested IPEX,
did not have a mutation in FOXP3, we investigated if these
two groups could be differentiated phenotypically by comparing
clinical and laboratory data of patients with FOXP3 mutations
(IPEX, n = 88) to those lacking an identifiable FOXP3 mutation
(IPEX-like, n= 85).
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MATERIALS AND METHODS
Patients
The study included 173 male patients from 143 unrelated
families referred to the two participating centers for mutational
analysis of the FOXP3 gene. A questionnaire was submitted to
each referring physician to collect pertinent clinical, laboratory
and demographic information on each patient at the time of
submitting DNA for sequencing. The requested information
included the patient’s age at diagnosis and the major clinical
manifestations, such as endocrinopathy, enteropathy, skin
disease, other autoimmune phenomena (i.e., hemolytic anemia
AHA, thrombocytopenia ITP, and neutropenia), and infections.
We also requested information about the immune status, type
of treatment, and response to therapy. Screening for genetic
mutations in FOXP3 was performed in patients who presented
with early-onset and/or severe clinical manifestations resembling
IPEX syndrome, in particular at least one of the major clinical
findings (enteropathy, endocrinopathy, skin disease) associated
with other autoimmune manifestations. Written informed
consent for genetic investigations, approved by the local ethics
committees, was obtained from each patient or a parent.
Genomic DNA Isolation, Amplification, and
FOXP3 Gene Sequence Analysis
Genomic DNA was isolated from peripheral blood using
the QIAamp DNA Blood Mini Kit (Qiagen, Germantown,
MD and Hilden, Germany) according to the manufacturer’s
protocol. The entire coding sequence of FOXP3, including
exon–intron junctions, was amplified using specific flanking
intron primer pairs as previously reported (8) and standard
PCR conditions. The upstream promoter region and a 348-bp
fragment encompassing the first polyadenylation signal 880-bp
downstream of the termination codon were also amplified using
previously described primers (42). PCR products were sequenced
using the BigDye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) on an automated ABI PRISM
3130 Genetic Analyzer (Applied Biosystems) and compared with
reported reference cDNA sequences, using guidelines provided
by HGVS and Mutalyzer 2.0.26.
Next Generation Sequencing (NGS)
Analysis of IPEX-Like Patients
A custom sequencing array was designed to target all coding
exons and flanking sequences for a panel of 50 genes that
are known to cause PIDs to investigate those patients without
identifiable FOXP3mutations (Supplementary Table 1).
The panel was designed using a custom target in solution
enrichment NimbleGen SeqCap EZ Choice Design (Roche
Inc., Madison, WI, USA) and included genes associated
with combined immunodeficiencies, immune dysregulation
disorders, innate immunity defects, and autoinflammatory
diseases. Genomic DNA (gDNA) was purified and resuspended
in water using the DNA Clean & Concentrator-5 columns (Zymo
Research Corporation, Irvine, CA, USA); 135 ng of purified
gDNA was used for the fragmentation reaction. The libraries
were prepared using the Kapa Hyperplus Kit according to the
manufacturer’s protocol (Kapa Biosystem), that provides for
the ligation of different adapters in order to analyze up to 24
samples in a single sequencing run. The pool was hybridized
to the SeqCap EZ Choice Library designed to capture the
genes included in the panel. Sequencing was performed using
the Illumina MiSeq platform according to the manufacturer’s
recommendations using MiSeq Reagent Kit v3 and a 150 bp
paired-end chemistry (Illumina, San Diego, CA, USA).
Sequence reads were aligned to the NCBI37/hg19 reference
genome using a pipeline based on BWA and Picard (https://
broadinstitute.github.io/picard/). Variants were called using the
GATK toolkit (43).
Variants were annotated with gene name and classified
according to their position and effect (frameshift, truncating,
splicing, coding non synonymous, coding synonymous,
intronic) using the ANNOVAR tool (44). Variants localized in
intronic regions outside the 30 bp exon flanking boundaries
were excluded. Variants reported in the Exome Aggregation
Consortium (ExAC) database (http://exac.broadinstitute.org/)
and/or in the 1000 Genomes Project (http://www.1000genomes.
org) and/or in the NHLBI Exome Sequencing Project (ESP,
ESP6500 database, http://evs.gs.washington.edu/EVS), with a
Minor Allele Frequency (MAF) >0.05 (5%) were dropped out.
To further determine the variant’s pathogenicity a systematic
classification scheme was applied using a combination of
prediction programs: SIFT (sift.bii.a-star.edu.sg), PolyPhen
(http://genetics.bwh.harvard.edu/pph2/), and pMUT (http://
mmb.pcb.ub.es/PMut/PMut.jsp) to distinguish potentially
damaging variants from those predicted to have neutral
effect.
Putative causative variants were analyzed by Sanger
sequencing to confirm the NGS results and investigated
in the parents of probands to check their inheritance
status.
Flow Cytometry of FOXP3+CD4+CD25+
Cells
Surface staining for CD4 and CD25 was performed by exposing
the cells to the anti-CD4 (SK3, BD Biosciences, CA) and
anti-CD25 (M-A251, BD Biosciences) monoclonal antibodies
for 15min in the dark using a 2% bovine serum albumin
phosphate-buffered saline (PBS) mixture on freshly isolated
PBMCs. Cells were washed in PBS and fixed for 30min
at 4◦C using the eBioscience fixation/permeabilization kit,
according to manufacturer’s instructions. After washing in
PBS and permeabilization (15min at 4◦C), the cells were
incubated overnight at 4◦C with anti-human FOXP3 antibody
(259D, BioLegend, San Diego CA), washed, examined by flow
cytometry (FASCanto II) and analyzed with FACSDiva Software
(BD Biosciences). FOXP3+ positive signal was evaluated by
comparing to the isotype signal. Gating strategy was performed
by selecting lymphocytes based on physical parameters; CD4+
cells were selected from the lymphocyte population, and
FOXP3+CD25+ cells from the CD4+ cell subpopulation. Values
of CD25+FOXP3+Tregs are given as percentage within the
CD4+ population.
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Statistical Analysis
We used a 2-sided 2-sample test of proportions to determine if
there is a difference in the occurrence of clinical manifestations
and in the levels of serum immunoglobulins between the
IPEX and IPEX-like groups at a significance level of ≤0.05.
Differences in age onset of symptoms between IPEX and IPEX-
like were evaluated by the Mann–Whitney test. Differences
in CD25+FOXP3+ Treg expression in IPEX, IPEX-like, and
control subjects were evaluated by the One-way ANOVA test.
Kaplan Meier Survival analysis was performed to determine
survival curves. A log rank test for equality of survivor functions
was performed to determine differences in survival curves at
a significance level of 0.05. All analyses were performed using
Graphpad Prism 6 software.
RESULTS
We aimed to perform a detailed molecular, immunologic, and
clinical evaluation of a cohort of patients presenting with
phenotypic features suggestive of a diagnosis of IPEX syndrome.
Based on the results of FOXP3 gene sequencing, we classified
patients into 2 groups: those with disease causing FOXP3
mutations (IPEX kindreds) and those without identifiable FOXP3
mutations (IPEX-like kindreds). To investigate whether the
clinical and immunologic features of our patients correlated with
this molecular categorization, we used a specifically designed
questionnaire to be completed for each patient by the referring
physician.
Molecular Analysis
IPEX Cohort With FOXP3 Mutations
Themolecular analysis of FOXP3 carried out in 173 patients from
143 unrelated families enrolled identified FOXP3 mutations in
88 affected patients (50.9%) from 66 (46.2%) unrelated families.
Overall, 44 distinct sequence variants of FOXP3were identified, 9
of which were not previously reported (Table 1). The mutations
were distributed throughout the FOXP3 gene, although the
majority were located within the functional domains, particularly
the repressor N-terminal domain, the leucine zipper and the
carboxy-terminal forkhead domain as shown in Figure 1. When
aligning the forkhead domain and the leucine zipper region of
the FOXP3 protein with members of other FOX protein family
members, the mutations tended to occur at the most highly
conserved residues (Figure 2).
Several residues with a high frequency of mutation rate
were identified, with 5 mutations accounting for almost 35%
of families (23/66) (Figure 1). These include three missense
mutations in the forkhead domain, one occurring in exon
9 (c.1010G>A, p.R337Q) and two in exon 11 (c.1150G>A,
p.A384T and c.1157G>A, p.R386H) and 2 single amino acid
deletions in the leucine zipper region at residues 250 and 251
located in exon 7.
We identified 4 IPEX patients carrying deletion/frameshift
mutations within exon 2 of the FOXP3 gene. In humans, two
major alternatively spliced FOXP3 mRNA species have been
described: the full-length (FL) isoform including all 11 coding
exons, and a splice isoform lacking exon 2 (Exon 2minus). Under
normal circumstances, the FL and exon 2minus isoforms are the
dominant species present, with each accounting for ∼50% of
the total FOXP3 mRNA in T cells (85–87). The two isoforms
encode two proteins that can both be detected in T cells from
normal individuals (85). The physiologic role of the short exon
2minus isoform is unknown but their potential role in supporting
Treg development has been investigated in a number of studies
(88–92). The 4 patients reported here have deletion mutations
in exon 2 that are predicted to cause a frameshift in the FL
mRNA resulting in premature termination and absence of full-
length mRNA that includes exon 2 while allowing expression
of a normal exon 2minus isoform of the protein. This was
demonstrated by flow cytometry when we stained activated T
cells from the patient with the c.239del mutation (and confirmed
in the patient with the c.232_233del) using two different anti-
FOXP3 antibodies, one that binds all FOXP3 isoforms and one
that binds only within the sequence of the protein encoded
by exon 2. The deletion mutations in exon 2 identified in the
remaining 3 patients lead to the expression of only the FOXP3
exon 2minus isoform. This was demonstrated by Western blot
when a genomic DNA fragment containing exons 1–7 from these
patients was cloned into the pcDNA3-NV5 vector; in contrast,
when a DNA fragment with wild type DNA fragment was cloned
into the vector, equal amounts of both isotypes were expressed
(Du, personal communication).
A second set of unique mutations identified in this large
cohort of IPEX are mutations in the mRNA polyadenylation
signal sequence of the FOXP3 gene. The polyadenylation signal
AAUAAA, located 798 bp downstream of the endogenous
termination codon of the FOXP3 gene triggers polyadenylation
of the FOXP3 mRNA, protecting it from degradation. A
single point mutation (AAUAAA > AAUGAA) was identified
in the first family described with IPEX syndrome (2, 42).
Patients with this mutation were found to have only low-level
expression of the FOXP3 mRNA [(42) and data not shown],
presumably due to increased degradation as a result of the
absence of an appended poly-A tail. Since the discovery of this
mutation, we have screened all patients with an IPEX phenotype
and a normal FOXP3 coding sequence for mutations in the
polyadenylation signal. As a consequence, we have identified
11 patients from 3 families with mutations in the FOXP3
polyadenylation signal sequence, suggesting that up to 12% of
patients with IPEX have mutations affecting the polyA site of
FOXP3, a region that is largely neglected in usual sequencing
approaches. Deletions of or mutations in the canonical polyA
signal (AAUAAA) are expected to prevent the normal generation
of the polyadenylated 3
′
-end of a gene, which provides a
signal for both cleavage and polyadenylation of pre-mRNA that
occurs in the nucleus. This process is crucial for the transport
of mature mRNA to the cytoplasm and for the stability of
mRNA (6, 93).
A sequence variant (c.543C>T), although resulting in a
synonymous amino acid substitution, was initially considered
pathogenic since it affects the first base of exon 5, potentially
resulting in a splicing defect. However, sequencing 200
chromosomes from a multiethnic population we found this
alteration in 3.5% of this group of healthy individuals. To
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TABLE 1 | Mutations identified in the cohort of patients analyzed.
Gene Exon cDNA Protein Mutation type No. of families References
FOXP3∧1 −1 c.-6247_4859del Large non-coding deletion Splicing 1 (45)
FOXP3 1 c.29_47del p.S10Lfs*46 Frameshift deletion 1 Unpublished
FOXP3 1+ c.210+1delG Miss-spliced protein Splicing 1 Unpublished
FOXP3 1+ c.210+1G>C Miss-spliced protein Splicing 1 (18)
FOXP3 1+ c.210+2del Miss-spliced protein Splicing 1 (46)
FOXP3 2 c.227del p.L76Qfs*53 Frameshift deletion 1 (8, 47–49)
FOXP3 2 c.232_233del p.M78Gfs*127 Frameshift deletion 1 Unpublished
FOXP3 2 c.239del p.A80Dfs*49 Frameshift deletion 1 Unpublished
FOXP3 2 c.303_304del p.F102Hfs*103 Frameshift deletion 1 (50)
FOXP3 3+ c.454+4A>G Miss-spliced protein Splicing 1 (51)
FOXP3 4- c.455-1G>C Miss-spliced protein Splicing 1 Unpublished
FOXP3 6 c.694T>G p.C232G Missense 1 (52)
FOXP3 6 c.725T>C p.L242P Missense 1 (53, 54)
FOXP3 7– c.736-2A>C Miss-spliced protein Splicing 1 (55)
FOXP3 7 c.748_750del p. K250del In Frame Deletion 3 (56–58)
FOXP3 7 c.751_753del p. E 251del In Frame Deletion 5 (5, 54, 59)
FOXP3 7 c.758T>C p.L253P Missense 1 (60)
FOXP3 7 c.767T>C p.M256T Missense 1 Unpublished
FOXP3 7+ c.816+2delT Miss-spliced protein Splicing 1 (61)
FOXP3 7+ c.816+3G>C Miss-spliced protein Splicing 1 Unpublished
FOXP3 7+ c.816+5G>A Miss-spliced protein Splicing 2 (53, 54)
FOXP3 7+ c.816+7G >C Miss-spliced protein Splicing 1 (62)
FOXP3 8 c.817G>T p.A273S Missense 1 (63)
FOXP3 9 c.967G >A p.E323K Missense 1 Unpublished
FOXP3 9 c.970T>C p.F324L Missense 1 (64, 65)
FOXP3 9 c.994A>G p.K332E Missense 1 Unpublished
FOXP3 9 c.1010G>A p.R337Q Missense 4 (66–68)
FOXP3 9 c.1037T>C p.I346T Missense 1 (61)
FOXP3 9 c.1040G>A p.R347H Missense 2 (61, 65)
FOXP3 10 c.1087A>G p.I363V Missense 1 (8, 56)
FOXP3 10 c.1099T>C p.F367L Missense 1 (69)
FOXP3 10 c.1110G>A p.M370I Missense 1 (70)
FOXP3 11 c.1150G>A p.A384T Missense 8 (7, 53, 71, 72)
FOXP3 11 c.1157G>A p.R386H Missense 3 (63)
FOXP3 11 c.1169G>A p.S390N Missense 1 (73)
FOXP3 11 c.1189C>T p.R397W Missense 2 (7, 56, 74)
FOXP3 11 c.1190G>A p.R397Q Missense 1 (63)
FOXP3 11 c.1222G>A p.V408M Missense 1 (66)
FOXP3 11 c.1226A>C p.D409A Missense 1 (75)
FOXP3 11 c.1227_1235del p.D409_L411del In Frame Deletion 1 (76)
FOXP3 11 c.1271G>A p.C424Y Missense 1 (56, 75)
FOXP3 11 c.1293_1294del p.*432Text25 Frameshift deletion 1 (6)
FOXP3 Poly A AAUAAA>AAUGAA Unstable mRNA 2 (42)
FOXP3 Poly A AAUAAA>AAUAAG Unstable mRNA 1 (77)
IL2RA∧2 2 c.151T>G p.C51G Homozygous Missense 1 Paper submitted
IL2RA 2 c.452A>C p.Q151P Homozygous Missense 1 Unpublished
LRBA∧3 21 c.2496C>A p.C832* Homozygous
Nonsense
1 Unpublished
LRBA 22 c.2617_2620del p.L873Afs*13 Homozygous
Frameshift deletion
1 Unpublished
(Continued)
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TABLE 1 | Continued
Gene Exon cDNA Protein Mutation type No. of families References
LRBA 36 c.5680A>T p.R1894* Homozygous
Nonsense
1 Unpublished
CTLA4∧4 2 c.436G>A p.G146R Heterozygous
Missense
1 Unpublished
CTLA4 2 c.410C>T p.P137L Heterozygous
Missense
1 (78)
STAT1∧5
GOF
12 c.1073T>G/T p.L358W Heterozygous
Missense
1 (37)
STAT1
GOF
14 c.1154 C>T/C p.T385M Heterozygous
Missense
1 (79)
STAT1
GOF
12 c.1053G>T/G p.L351F Heterozygous
Missense
1 (80)
STAT1
GOF
11 c.983A>G/A p.H328R Heterozygous
Missense
1 (81)
STAT3∧6
GOF
9 c.832C>T/C p.R278C Heterozygous
Missense
1 Unpublished
STAT3
GOF
10 c.986T>G/T p.M329R Heterozygous
Missense
1 Unpublished
STAT3
GOF
11 c.1079A>G/A p.Y360C Heterozygous
Missense
1 Unpublished
STAT3
GOF
14 c. 1243 G>C/G p.E415Q Heterozygous
Missense
1 Unpublished
STAT5b∧7 9 c.1680+1del Splicing 1 (82)
TTC7A∧8 c.1817A>G/A;
c.2086T>C
p.E606G, p.S696P Compound
Heterozygous
Missense
1 (83)
TTC37∧9 33 c.859-3_859-
7delTTTTT,
c.3364delA
Miss-spliced protein, p.T1122Qfs*10 Compound
Heterozygous
Frameshift, Splicing
1 Unpublished
DOCK8∧10 27 c.3193del p.S1065Afs*17 Homozygous
Frameshift
1 (84)
Nomenclature according to HGVS, using Mutalyzer 2.0.26 Name Checker and gene specific transcript variants. 1FOXP3, NM_014009.3; 2 IL2RA, NM_000417.2; 3LRBA, NM_006726.4;
4CTLA4, NM_005214.4; 5STAT1, NM007315.3; 6STAT3, NM_139276.2; 7STAT5b, NM_012448.3; 8TTC7A, NM_001288951.1; 9TTC37, NM_014639; 10DOCK8, NM_203447.1;
(PolyA, Polyadenylation site; fam, families).
further evaluate the function of the splicing machinery in cells
with the c.543C>T variant, we activated PBMCs from such
patients to induce FOXP3 expression and then cloned and
sequenced individual mRNA. We found that in individuals with
the c.543C>T alteration less than 5% of the transcriptsmisspliced
around exons 4–5, compared to 0% in the controls. We do
not believe this is enough dysfunction to result in the IPEX-
like phenotype seen in these individuals, and therefore excluded
them.
Another variation we reported previously (c.112G>T, p.A38S)
(56), has been confirmed to be nonpathogenic. This alteration
showed little difference from a wild-type FOXP3 vector in
repression of a luciferase reporter containing an IL2 promoter.
We had identified this variation in a family with 2 boys
who presented with a severe IPEX-like phenotype including
autoimmune enteropathy, eczema, diabetes, hypothyroidism,
and nephrotic syndrome; both died prior to age 5. However,
approximately 50% of asymptomatic men in this family were also
found to have this alteration. For this reason, these boys have
been included in the IPEX-like cohort.
IPEX-Like Cohort With Wild Type FOXP3
Overall, 85 patients (49.1%) with phenotypic features of IPEX
from 77 unrelated families (53.8%) had no identifiable mutations
in FOXP3. They were designated as IPEX-like and all Italian
patients were evaluated for variants by a multiplex panel
that included 50 genes involved in known PIDs. The Seattle
patients were evaluated by Sanger sequencing of candidate
genes (STAT5b, STAT1, STAT3, IL2RA, CTLA4, LRBA, TTC7A,
TTC37). In this cohort of 85 affected individuals, 25 different
disease-associated variants were identified in 21 IPEX-like
patients (25%) affecting 9 distinct genes (Table 1). Seven of the
nine genes had previously been associated with a phenotype of
immune dysregulation including LRBA, STAT1 (GOF), STAT3
(GOF), CTLA4, IL2RA, STAT5B, and DOCK8. In particular, the
“gain of function” mutations affecting the genes STAT1 and
STAT3 account for 38% of the mutations identified in our IPEX-
like cohort (8/21). All mutations identified in LRBA are novel
and homozygous, two being nonsensemutations and one causing
a frameshift; all are predicted to result in the absence of the
protein or the formation of a truncated-dysfunctional protein.
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FIGURE 1 | FOXP3 mutations identified in our cohort of IPEX patients. Schematic representation of FOXP3 mRNA and protein showing the location and sizes of the
predicted structural domains. Numbers along the top line indicate amino acid number (1–431). The position of the identified mutations along the mRNA is reported
with different shape for each type of variation. Each symbol represents a single kindred. ZF, zinc finger; LZ, leucine zipper; FKH, forkhead box domain; N, amino
terminus; C, carboxy terminus; PolyA, polyadenylation sequence.
FIGURE 2 | (A) FOXP3 mutations in IPEX (symbols in yellow) in forkhead box domain. Amino acid sequence of FOXP3 protein aligned with other FOX proteins. Shows
conserved residues (blue) and highly conservative residues (green). (B) FOXP3 mutations in IPEX (symbols in yellow) in leucine zipper domain. Amino acid sequence of
FOXP3 protein aligned with c-myc and v-myc leucine zippers (known to be highly conserved). Shows highly conserved residues (blue) and highly conservative
residues (green).
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FIGURE 3 | (A) CD25+FOXP3+ expression in IPEX, IPEX-like patients and control subjects. (B) IPEX patients differ according to the type of FOXP3 mutations.
Deletion = in frame deletion; frameshift = deletion with frameshift. Values are expressed as percentage of CD4 cells, median and 5–95 percentile are shown, circles,
triangles, and cones represent singles patients out of 5–95 percentile (circles = IPEX patients, triangles = IPEX-like patients, cones = control subjects) (**p < 0.001;
***p < 0.0001).
This is in agreement with most LRBA mutations reported to
date (94).
All STAT3 and STAT1 mutations observed in our cohort
are heterozygous missense variants. One of the four STAT3
mutations located in the DNA binding domain, had been
previously reported as GOF mutation (78). Similarly, all STAT1
mutations are located in the DNA binding domain and had been
reported as GOF mutations by others (37, 79–81).
Mutations affecting CTLA4 include two heterozygous
missense variants, located in the extracellular domain of the
protein: one had been reported to be associated with immune
dysregulation (78, 95).
The IL2RA mutations identified include two novel
homozygous missense variants, located in exons 2 and 4
that constitute the two “sushi” domains essential for IL2-IL2Rα
interaction (96). These variants are associated with CD25
deficiency and will be reported in more detail separately.
The variants affecting STAT5B, a homozygous deletion
resulting in a splicing defect, has been reported to be
associated with Insulin-like growth factor (IGF) deficiency and
immunologic defects (82).
Mutations in the dedicator of cytokinesis 8 (DOCK8)
gene cause a combined immunodeficiency extending beyond
recurrent infections to include atopy, autoimmunity and cancer
(97, 98). DOCK8 deficiency has recently been identified in a
patient with an IPEX-like disorder (99). Three brothers with
IPEX-like phenotype were originally evaluated in our Centers
and found to have wild type FOXP3. Subsequently, a homozygous
single nucleotide deletion was identified in exon 27 of theDOCK8
gene, resulting in frameshift and premature termination (84).
The two other genes we identified to be associated with
IPEX-like Syndrome (TTC37, TTC7A) have not been
implicated previously with immune dysregulation. The
tetratricopeptide repeat domain 37 (TTC37) gene, if mutated,
causes Trichohepatoenteric Syndrome (THES), a rare autosomal
recessive disorder characterized by growth restriction, severe
infantile diarrhea, trichorrhexis nodosa-like hair morphology,
hepatopathy, facial dysmorphism, and immunodeficiency (100).
The tetratricopeptide repeat domain 7A (TTC7A) gene is
causative of hereditary multiple intestinal atresia (HMIA) (83), a
rare cause of intestinal obstruction associated with a profound
combined immune deficiency. Although these 2 disorders have
not been directly associated with an IPEX-like phenotype,
their clinical presentation can overlap. One of the compound
heterozygous mutations in TTC7A identified in our patient
has been previously described (83) while the two variants we
observed in our patient with the TTC37 were not.
The 21 detected variants associated with IPEX-like phenotype
include 13 missense, 2 nonsense, 4 frameshift, and 2 splicing
defects. Nine variants have previously been reported as disease
causing in the Human Gene Mutation Database (HGMD; http://
www.hgmd.cf.ac.uk/).
Treg Analysis by Flow Cytometry
To evaluate whether FOXP3 expression is normal or reduced
in patients with IPEX and IPEX-like Syndromes, we compared
41 IPEX patients and 34 IPEX-like patients with control
samples (n = 75) by flow cytometry. The percentage of
FOXP3 expression by CD4+ lymphocytes in IPEX and IPEX-
like patients was significantly lower compared to controls
(Figure 3A). We also evaluated whether the percentage of
FOXP3 expressing cells differed by the type of FOXP3mutations
(Figure 3B) and found very low to almost no protein expression
in patients with either in-frame or frameshift deletions, or
polyadenylation site mutations, and variable expression in
patients with missense and splicing mutations. Interestingly,
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FIGURE 4 | CD25+FOXP3+ expression in IPEX-like patients differed by the
type of mutated genes identified and control subjects. Values are expressed as
percentage of CD4 cells, mean and SD are shown.
two patients with missense mutations (p.E323K, p.S390N) had
markedly elevated percentages of FOXP3 expressing CD4+ cells,
which likely represent poor FOXP3 function, suggesting that the
level of protein expression does not necessarily correlate with
disease severity.
In IPEX-like patients with mutations in IL2RA the percentage
of CD4+FOXP3+ cells was within normal range, while CD25
expression, as expected, was absent, indicating a preservation of
Treg quantity, but defective function (data not shown). Analysis
of CD25 by flow cytometry in IPEX-like patients is essential
to identify patients with CD25 deficiency. FOXP3+Tregs were
evaluated in two of four patients with mutations in the LRBA
gene. Both patients had a reduction in the percentage of Treg
cells, in line with recently published data on patients with LRBA
deficiency (35). In patients with CTLA4 deficiency the frequency
of CD4+ Treg cells was normal or slightly decrease, suggesting
that autoimmunity in these patients is caused by defective Treg
function. Similarly, patients with STAT1 GOF or STAT3 GOF
mutations had variable percentages of Treg cells, with a general
tendency to decreased, but statistically not significant, values
(Figure 4).
Clinical Phenotypes of IPEX and IPEX-Like
Patients
The clinical data obtained from IPEX and IPEX-like patients
included in this study are summarized in Figures 5A,B and
Supplementary Table 2. Enteropathy was the most consistent
finding in both groups of patients (IPEX 97% vs. IPEX-like 96%,
p = 1) and is most commonly associated with watery diarrhea,
with a minority of patients reporting blood or mucus in the
stools. Diarrhea begins within the first few months of life in the
majority of patients in both groups.
For patients in whom age of onset was known, the mean
age at onset of enteropathy among the IPEX patients was 7.8
months compared to 17.3 months in the IPEX-like patients (p
= 0.15). Histologically, the incidence of villous atrophy on small
bowel biopsy was similar (IPEX 45% vs. IPEX-like 34%, p =
0.16). Food allergies (which were defined as either an abnormal
RAST IgE or clinical evidence of allergy to foods) were present
more frequently among patients in the IPEX group (IPEX =
36% vs. IPEX-like 11%, p < 0.0001) and were reported as being
“severe” in most cases. In one patient, the food allergies resolved
after successful hematopoietic stem cell transplantation (HSCT).
Not surprisingly, many patients from both groups suffered from
failure to thrive (IPEX 75% vs. IPEX-like 71%, p= 0.61) which is
likely due to persistent enteropathy, malabsorption, and chronic
disease.
Skin manifestation were also widespread among both groups
of patients (IPEX 89% vs. IPEX-like 75%, p = 0.03). There
was however a greater difference in the incidence of eczema
and/or exfoliative dermatitis (IPEX 85% vs. IPEX-like 65%, p =
0.003). Erythroderma (IPEX 8% vs. IPEX-like 11%, p = 0.6) and
childhood alopecia (IPEX 11% vs. IPEX-like 15%, p = 0.5) were
reported in both groups.
Autoimmune endocrinopathies, which most commonly
include type I diabetes mellitus (T1DM) and hypo- or
hyperthyroidism and, in a few patients, adrenal insufficiency,
were seen at a similar frequency among the IPEX and IPEX-
like patients (IPEX 65% vs. IPEX-like 59%, p = 0.44). However,
there was almost a two-fold difference in the number of patients
with T1DM in the IPEX cohort compared to the IPEX-like
group (IPEX 49% vs. IPEX-like 28%, p = 0.008). For those with
known age of onset of T1DM, IPEX patients tended to present
earlier (mean = 27 months) than the IPEX-like patients (mean
= 36 months) (p = 0.009). A few patients in both groups had
positive Anti-glutamic acid decarboxylase (GAD) antibodies or
Anti-islet cell antibodies in the absence of clinical disease (IPEX
n = 5, IPEX-like n = 5). Interestingly, one carrier mother with
a heterozygous mutation of FOXP3, had clinical evidence of
T1DM.
Clinical thyroid disease (defined as having abnormal Thyroid
Stimulating Hormone [TSH], triiodothyronine [T3], or free
thyroxine [T4] with or without symptoms) was slightly more
prevalent in the IPEX-like group (IPEX 26% vs. IPEX-like 39%,
p = 0.10). A small number of patients in both groups had
evidence of autoantibodies against thyroid (anti-microsomal or
anti-thyroglobulin) but lacked evidence of clinical disease (IPEX
n= 3, IPEX-like n= 5).
When evaluating patients for the presence of the classic triad
of enteropathy, endocrinopathy, and skin manifestations, IPEX
patients were more likely to be affected by all three (IPEX 58% vs.
IPEX-like 44%, p= 0.07).
Of the other autoimmune phenomena typically associated
with IPEX syndrome, hematologic abnormalities were equally
present in both groups (IPEX 42% vs. IPEX-like 44%, p =
0.88), including anemia (IPEX 33% vs. IPEX-like 42%, p =
0.87), neutropenia (IPEX 13% vs. IPEX-like 15%, p = 0.66),
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FIGURE 5 | Clinical manifestations in the IPEX and IPEX-like cohorts (A). IPEX patient stratified for type of mutation showing classical triad of symptoms (B).
FIGURE 6 | Heat map showing frequencies of clinical manifestations in our cohort of patients with LRBA, CTLA4, STAT1 GOF, STAT3 GOF, STAT5b, and IL2RA
mutations.
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and thrombocytopenia (IPEX 22% vs. IPEX-like 20%, p =
0.85). Organ and non-organ specific autoantibodies were also
present in both groups (IPEX 17% vs. IPEX-like 26%, p =
0.26).
Renal abnormalities were common in both groups (IPEX 28%
vs. IPEX-like 25%, p= 0.61) characterized by glomerulonephritis,
interstitial nephritis, unexplained hypertension, persistent
hematuria, or proteinuria. Hepatic abnormalities, most
commonly autoimmune hepatitis, were found in both groups
(IPEX 20% vs. IPEX-like 20%, p = 1). Pulmonary disease, such
as asthma and interstitial lung disease (IPEX 23% vs. IPEX-like
27%, p = 0.60), lymphadenopathy (IPEX 14% vs. IPEX-like
19%, p = 0.41) were reported in both groups, although slightly
more prevalent in the IPEX-like cohort. Arthritis or vasculitis
(IPEX 9% vs. IPEX-like 11%, p = 0.80) were equally described.
Few patients suffered from cardiovascular disease, mostly in the
IPEX-like group (IPEX 2% vs. IPEX-like 5%, p = 0.44). This
included pericarditis, atrial flutter, dilated aortic root, pericardial
effusion, and aneurisms.
Approximately a quarter of patients in both groups were
reported to have neurologic abnormalities (IPEX 24% vs. IPEX-
like 28%, p = 0.60) including seizure disorders (IPEX 14% vs.
IPEX-like 7%, p = 0.21), ventriculomegaly (IPEX 3% vs. IPEX-
like 5%, p= 0.72), and developmental delay (IPEX 14% vs. IPEX-
like 24%, p= 0.12), which, in our cohort, is higher than has been
reported in the literature.
Serious infections were reported in almost half of all patients
and included sepsis, meningitis, peritonitis, and pneumonia
(IPEX 47% vs. IPEX-like 44%, p = 0.76). The most common
organisms identified were Staphylococcus (IPEX 23% vs. IPEX-
like 20%, p = 0.71), Cytomegalovirus (IPEX 10% vs. IPEX-like
7%, p = 0.59), and Candida (IPEX 19% vs. IPEX-like 15%, p =
0.55).
In order to assess a possible genotype-phenotype correlation
within the IPEX cohort, we stratified IPEX patients for
mutation type (frameshift/in frame deletion/missense/splice
site/polyadenylation mutations) and correlate the genotype with
the development of the classical clinical triad of immune
dysregulation (Figure 5B). The complete phenotype was mainly
present in patients affected by in-frame deletions (83%) and
frameshift mutations (67%). In the other genotypes the clinical
presentation resulted to be variable. Similarly, patients lacking
exon 2 show a phenotype which do not significantly differ
from other IPEX genotypes. However, the severity of symptoms
is somehow unpredictable and not necessarily related to the
mutation type.
Among the IPEX-like cohort, patients with mutations in
genes related to Treg function (i.e., CD25, STAT5b, STAT3 and
STAT1 GOF, LRBA, CTLA4) are affected by a clinical phenotype
strongly resembling IPEX. Most of them suffer from the classical
clinical triad of immune dysregulation symptoms (enteropathy,
skin disease, and endocrinopathy). All patients with heterozygous
CTLA4mutations and patients with LRBAmutations suffer from
autoimmune cytopenias. The majority of LRBA patients (75%)
also developed lymphoadenopathy and/or hepatosplenomegaly,
whereas serious viral and bacterial infections seem to cluster
mainly in subjects with mutations in CD25, STAT1GOF, and
FIGURE 7 | IgE levels in IPEX and IPEX-like patients. Mean and SD are shown
(****p < 0.0001).
STAT5bmutated subjects. Food allergies were not reported in this
group (Figure 6).
Laboratory Findings
Immunoglobulin levels were generally normal in both groups
of patients, except for elevated IgE levels in 92% of IPEX
and 49% (p < 0.0001) of IPEX-like patients. IgE levels were
>1,000 IU/ml in 59% of IPEX patients and 25.5% (p = 0.0005)
of IPEX-like patients, some in each group having levels over
10,000 IU/ml (Figure 7). Hypogammaglobulinemia, if present,
was associated mostly with LRBA, STAT3 GOF, and heterozygous
CTLA4 mutations. Absolute lymphocyte counts and CD4+ and
CD8+ lymphocyte subsets were normal in most IPEX and IPEX-
like patients. In vitro lymphocyte proliferation in response to
mitogens and antigens were also normal in most patients as well
as antibody responses to immunization with protein antigens
(data not shown).
Treatment
Most IPEX patients responded at least temporarily to the
combination of steroids with either cyclosporine A, tacrolimus,
or sirolimus. However, many patients in both groups had only
marginal or poor responses to therapy with steroids alone.
Hematopoietic stem cell transplantation (HSCT) was performed
in 40 IPEX patients and 15 IPEX-like patients. Nine patients
with IPEX (22.5%) but only one with IPEX-like syndrome
died post-transplantation from transplant- and disease-related
complications. Most surviving patients had resolution of their
enteropathy and skin disease post-transplantation, whereas
T1DM, when present at the time of transplantation, persisted.
Prognosis
Time (in years) of follow-up since birth was obtained on 163 out
of 173 patients.
Overall, long term survival (30 years) of all patients evaluated
(n= 163) was 47.5% (Figure 8A). When comparing survival data
Frontiers in Immunology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 2411
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
Gambineri et al. IPEX and IPEX-Like: Clinical and Molecular Heterogeneity
between IPEX and IPEX-like patients, we observed that long term
survival (30 years) was poor in both groups of patients with better
survival rate in the IPEX group (52% IPEX vs. 27% IPEX-like),
but with a greater 10-year survival in the IPEX-like group (81.5%)
compared with IPEX patients (65%) (Figure 8B). When stratified
by the type of mutation, we observed the highest 10-year survival
in patients with in frame deletions (87.5%), followed by splice site
mutations (78%), missense mutations (67%), frameshift (67%),
and polyadenylation site mutations (19%) (Figure 8C).
When stratifying the IPEX-like cohort into two groups,
subjects with a single gene defect (IPEX-like with mutation) and
those without an identified genetic defect (IPEX-like without
mutation) and then comparing survival data in these two IPEX-
like groups with IPEX patients, we observe a higher long-
term survival (20 years) in IPEX-like without mutation (78.3%)
compare with IPEX patients (62.4%) and with IPEX-like with
mutations (44.4%) (Figure 8D). IPEX patients showed the worst
early survival (10-year survival) when compared with the other
groups.
Finally, we evaluate the effect of HSCT both in the IPEX and
IPEX-like groups. We observed a 10-year survival of 72.8% in
IPEX patients who underwent HSCT (n= 38) and 57.3% in non-
transplanted (n= 46) IPEX patients (p= 0.02) (Figure 8E). After
15 years, several transplanted IPEX patients were lost to follow-
up causing the drop in survival curve. In the IPEX-like cohort we
observed a 10-year survival of 100% in transplanted patients (n=
10) and 78% in non-transplanted (n = 68) patients (p < 0.0001)
(Figure 8F).
DISCUSSION
IPEX is a syndrome of systemic autoimmunity caused by
mutations in FOXP3, which codes for a member of the
forkhead transcription factor family, expressed primarily in
CD4+CD25+ regulatory T cells. A similar syndrome is caused
by the naturally occurring Foxp3 mutation in mice resulting
in the scurfy phenotype characterized by diarrhea, runting, a
scaly skin rash, anemia, thrombocytopenia, lymphadenopathy,
hepatosplenomegaly, and early death. To define the clinical
phenotype associated with mutations in FOXP3, we collected
data from 177males from 143 unrelated families with phenotypic
features of IPEX, who were referred to us for mutation analysis
and of which 88 had mutations in FOXP3.
The 44 unique FOXP3 mutations identified in our cohort of
IPEX patients clustered in the functional domains, particularly
in the leucine zipper and forkhead (FKH) domains. Residues
located in the FKH domain play a role in the interaction
of FOXP3 with NFAT, NF-KappaB, DNA binding, and the
formation of domain swapped dimers (101–103). Several “hot-
spot” mutations were identified in FOXP3 with four of these
mutations accounting for IPEX in almost 1/3 of the families:
two of these hot-spot mutations were single amino acid deletions
located in the leucine zipper region (p.K250del and p.E251del)
found in 8 patients, and two were missense mutations in the
FKH domain, p.R337Q and p.A384T, affecting one of the DNA
binding site residues, observed in 12 patients. The p.A384T
mutation is commonly associated with a mild phenotype and has
recently been shown to impair the suppressive function of Treg
cells while maintaining most aspects of FOXP3 transcriptional
functions including the ability to repress inflammatory cytokines.
The impaired suppressive function of Tregs with the p.A384T
substitution is in part due to a specific disruption of the binding
of the mutated FOXP3 to the histone acetyltranferase Tat-
interacting protein 60 (TIP60); this defect can be corrected
using allosteric modifiers that enhance FOXP3-TIP60 interaction
(104).
FOXP3 expression varied in IPEX patients depended on the
types of mutation with low or lack of expression associated
with in-frame and frameshift deletion mutations, low expression
in polyadenylation site and splicing mutations, and variable
expression in patients with missense mutations. IPEX-like
patients were found to have generally low levels of FOXP3
expression compared to controls, in particular those affected by
mutations in genes related to Treg function (i.e., LRBA, CTLA4).
This finding is expected since the scurfy/IPEX phenotype is
explained by extensive immune dysregulation resulting from
the absence or abnormal function of CD4+CD25+ regulatory T
lymphocytes.
Of the 143 families (173 patients) analyzed, 63 families
(77 patients) had mutations within the coding region of
FOXP3 or exon-intron junctions. Three families with multiple
affected members were identified to have FOXP3 mutations in
the canonical Poly-A region 878–883 bp downstream of the
termination codon. Two families had the AAUAAA> AAUGAA
mutation originally described by Bennett et al. (42), one of which
is the family reported by Powell et al. (2). Affected members of
the other family carried the AAUAAA > AAUAAG mutation.
Additional reports of Poly-A mutations causing IPEX suggest
an unusually high incidence of mutations in the Poly-A site
of FOXP3 (60, 61, 77). In the PID field, only 2 cases of X-
linked SCID due to Poly-A mutations (AAUAAA > AAUAAG)
in the IL-2Rgamma chain were reported [(105) and Walter
J, unpublished]. Mutations affecting the canonical Poly-A site
are rare, except in patients with alpha Thalassemia due to
Poly-A mutations in the alpha-globulin gene (106, 107), or in
patients with beta-Thalassemia due to Poly-A mutations in the
beta-globulin gene (108, 109). The remaining 77 families (85
patients) had a similar phenotype but without demonstrable
mutations in the coding region, the upstream non-coding
region, or the polyadenylation site of FOXP3. These patients
were termed “IPEX-like” patients. The clinical findings of
these two groups of patients are summarized in Figure 5 and
Supplementary Table 2. IPEX patients more likely had food
allergies, eczema, T1DM, as well as the full triad of classical
symptoms (enteropathy, skin disease, and endocrinopathy),
while IPEX-like patients seemed to be more frequently affected
by thyroid disease and cardiovascular abnormalities.
Much of what is known about the clinical characteristics of
IPEX syndrome is derived from case reports (2–8, 42, 45, 52–
54, 57, 58, 66–68, 70, 71, 73) or reviews (110, 111). Compared
to the literature we found in our IPEX cohort a higher frequency
of characteristics that had been associated with this syndrome,
likely the result of a more comprehensive data collection. Some
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FIGURE 8 | Kaplan-Meier survival curve for overall survival of patients. (A) The overall survival in the whole cohort of patient is evaluated (n = 163); (B) IPEX (n = 85)
vs. IPEX-like (n = 78) patients are compared; (C) IPEX patients stratified for type of mutation: frameshift (FS) n = 6, in frame deletion (IFD) n = 11, missense (MS) n =
43, splicing mutations (SP) n = 14 and mutations in polyadenylation site (POLA) n = 11 are compared; (D) IPEX-like without mutations (NA= not available) n = 57 and
IPEX-like with mutation (Mut) n = 21 are compared; (E) IPEX patient stratified whether (n = 39) or not (n = 46) they underwent HSCT and (F) IPEX-like patient
stratified whether (n = 10) or not (n = 68) they underwent HSCT.
features were strikingly frequent in the IPEX group, including
failure to thrive, food allergies, alopecia, and the presence of the
complete “classic triad.” Neurologic abnormalities were present
in 28% of our patients including seizures, developmental delay
or ventriculomegaly. The incidence of neurologic abnormalities
was almost 3 times as high as reported by Barzaghi et al. (111).
Central nervous involvement may represent an autoimmune
phenomenon, however we presume to be probably caused by
chronic disease and immuno-suppressive therapy, especially
since IPEX-like patients seem to be equally affected. Similarly,
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FIGURE 9 | Flow chart suggesting molecular analysis strategy based on patients’ clinical phenotype and immunological markers.
the severe infections that are quite common in both groups,
considering the pathogens involved (i.e., Staphylococcus, Candida
albicans, Cytomegalovirus), are most likely a complication of
intense and prolonged immune suppression rather than a
consequence of an imbalanced immune system.
While elevated in both groups, IPEX patients had significantly
higher levels of IgE compared to IPEX-like patients, possibly a
useful diagnostic tool.
The long-term (30 years) survival of both groups is poor
(52% IPEX vs. 27% IPEX-like). However, the 10-years survival
of 81.5% in the IPEX-like group, particularly in those patients
not genetically defined, is significantly higher when compared
with the IPEX cohort (65%). This suggests that while there
is a difference in the survival curves, depending on the
presence and type of the FOXP3 mutation or the presence
of a mutation in related genes, the long-term consequences
of chronic autoimmunity and immunosuppressive therapy and
resulting infections are affecting outcome and patients’ quality of
life. In both, the IPEX and IPEX-like cohorts, HSCT improves
the survival rate, supporting early HSCT as curative treatment
(Figures 8E,F).
The progress of DNA sequencing technologies has
rapidly expanded the group of IPEX-like disorders caused
by mutations in genes coding for proteins involved
primarily (i.e., IL2Ra, STAT5b, CTLA4) and secondarily
(i.e., LRBA, STAT3-GOF, STAT1-GOF) in Treg generation
and function, by playing important roles in maintaining
immune homeostasis (112). However, the phenotypes of these
genetically diverse entities are often overlapping and a definite
diagnosis requires sophisticated molecular and functional
analyses.
We were surprised to identify several genes in our IPEX-
like cohort that were not directly linked to immune regulation.
Mutations in TTC7A (83, 113) and TTC37 (100, 114) have
been associated with severe diarrhea, villous atrophy, recurrent
infections and (in TTC7A) a SCID-like phenotype with multiple
intestinal atresia. DOCK8 deficiency shares with IPEX some
features such as atopic dermatitis, autoimmunity, recurrent
infections including muco-cutaneous candidiasis but, with few
exceptions (99), not inflammatory bowel disease. While the
clinical phenotypes of these conditions are generally quite
dissimilar from IPEX and IPEX-like disorders, they should be
considered in the differential diagnosis.
In conclusion, we have investigated the clinical features,
immunologic characteristics and molecular basis of 173
consecutive patients with a phenotype compatible with IPEX.
While half of the group had IPEX caused by a pathogenic
mutation in the FOXP3 gene, the other half did not. In the
IPEX cohort, we were able to link certain clinical features
with mutation type and location of the variant in the FOXP3
gene. To identify a possible genetic cause, we used a multiplex
platform and Sanger sequencing of candidate genes which
revealed a single gene defect in 27% of our cohort of 85
IPEX-like patients, involving 9 different genes, allowing
genotype-phenotype comparisons. While we did not find
unambiguous differences between IPEX and IPEX-like (with
or without a mutation) patients, we nevertheless attempted
to design a simple flow chart to assist in selecting an efficient
diagnostic strategy (Figure 9). However, with the increasing
number of relevant gene defects and the realization that
atypical presentations are the norm, single gene sequencing
is increasingly replaced by Next Generation Sequencing that
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includes designer multiplex platforms and Whole Exome
Sequencing.
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